| Literature DB >> 35008738 |
Ya Zhang1, Ke Gao1, Chong Wang2, Shuangqing Liu1.
Abstract
The aim of the present investigation was to determine the active ingredients in Amaranthus tricolor L. leaves and develop a biological pesticide. Organic solvent extraction, column chromatography, liquid chromatography, ODS-C18 reverse elution, Sephadex LH-20 gel filtration, H spectrum, and C spectrum were used to isolate the pure product for an assessment of the agricultural activity and bacteriostatic mechanisms. The results showed that the activity of the crude extract following carbon powder filtration was 1.63-fold that of the non-filtered extract. Further isolation was performed to obtain two pure products, namely, hydroxybenzoic acid (HBA) and benzo[b]furan-2-carboxaldehyde (BFC), and their molecular formulas and molecular weights were C7H6O3 and 138.12, and C9H6O2 and 146.12, respectively. Our study is the first to determine that HBA has bacteriostatic activity (MIC 125 μg/mL) and is also the first to isolate BFC from A. tricolor. The ultrastructure observation results showed that HBA caused the bacteria to become shriveled, distorted, and deformed, as well as exhibit uneven surfaces. After HBA treatment, 70 differentially expressed metabolites were detected in the bacteria, of which 9 were downregulated and 61 were upregulated. The differentially expressed metabolites were mainly strigolactones, organic acids and derivatives, fatty acids, benzene and substituted benzene derivatives, amino acids and associated metabolites, and alcohols and amines. Among all of the downregulated differentially expressed metabolites, MEDP1280 was the most critical, as it participates in many physiological and biochemical processes. The enrichment analysis showed that the differentially expressed metabolites mainly participate in tyrosine metabolism, biosynthesis of amino acids, cysteine and methionine metabolism, and arginine and proline metabolism. Additionally, HBA was found to disrupt cell membrane permeability and integrity, causing the leakage of substances and apoptosis. The physiological and biochemical test results showed that HBA could increase the pyruvate levels in bacteria but could decrease the activities of respiratory enzymes (malate dehydrogenase (MDH) and NADH oxidase) and antioxidant enzymes (superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX)). Inverse molecular docking was used to study the binding between HBA and respiratory and antioxidant enzymes. The results showed that HBA could bind to MDH, NADH oxidase, SOD, and GSH-PX, suggesting that these enzymes may be the effector targets of HBA.Entities:
Keywords: Amaranthus tricolor; bacteriostatic component; enzymatic activity; identification; metabolome; molecular docking; ultrastructure observation
Mesh:
Substances:
Year: 2021 PMID: 35008738 PMCID: PMC8745224 DOI: 10.3390/ijms23010312
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Antibacterial activity of ethyl acetate extract before and after elution by carbon column chromatography. (A) Treated by carbon column; (B) not treated by carbon column; (C) blank control.
Figure 2Morphology and structure identification of HBA. Note: (A) physical state; (B) structural formula; (C) 1H-NMR diagram of HBA (500 MHz, MeOD); (D) 13C-NMR of HBA (126 MHz, MeOD).
Figure 3Morphology and structure identification of BFC. Note: (A) physical state; (B) structural formula; (C) 1H-NMR diagram of BFC (500 MHz, MeOD); (D) 13C-NMR of BFC (126 MHz, MeOD).
Inhibition effect of three fungicides against A. avenae subsp. citrulli.
| Compound | Inhibition Zone Diameter (cm) |
|---|---|
| Average Value | |
| HBA | 2.29 ± 0.05 a |
| BFC | 0.54 ± 0.02 b |
| Zhongshengmycin (positive control) | 2.23 ± 0.01 a |
Note: Different lowercase letters indicate significant differences at the p < 0.05 level.
Figure 4Determination of MIC value of novel fungicide HBA against A. avenae subsp. citrulli. Note: HBA: 4-hydroxybenzoic acid; BFC: benzo[b]furan-2-carboxaldehyde; ZSM: zhongshengmycin; CK: control.
Figure 5Morphology and structure alterations of HBA-treated A. avenae subsp. citrulli observed by SEM. Note: (A1,B1): The control A. avenae subsp. citrulli with 5000 times. (C1,D1): The control A. avenae subsp. citrulli with 10,000 times. (A2,B2): The treated A. avenae subsp. citrulli with 5000 times (125 μg/mL). (C2,D2): The treated A. avenae subsp. citrulli with 10,000 times (125 μg/mL).
Figure 6Metabolite’s analysis of HBA-treated A. avenae subsp. citrulli by LC-MS/MS. Notes: (A): OPLS-DA score plot; (B): OPLS-DA verification diagram; (C): OPLS-DA S-plot; (D): difference metabolite volcano map; (E): difference metabolites and dazzle diagram; (F): difference metabolite network diagram; (G): difference metabolites KEGG enrichment; (H): biosynthesis of amino acids difference metabolites KEGG pathway; (I): cysteine and methionine difference metabolites KEGG pathway.
Significantly different metabolites putatively identified by UPLC-MS/MS.
| Number | Index | Formula | Compounds | Log2FC | Type |
|---|---|---|---|---|---|
| 1 | MW0152046 | C22H27NO5 | Kreysigine | 12.87 | up |
| 2 | MW0169908 | C24H48O2 | Tetracosanoic acid | 12.52 | up |
| 3 | MEDN1492 | C8H8O3 | (R)-(-)-Mandelic acid | 11.96 | up |
| 4 | MEDN0343 | C7H10O5 | Shikimic Acid | 11.61 | up |
| 5 | MEDL01916 | C6H6O | Phenol | 5.68 | up |
| 6 | MEDN1167 | C7H6O3 | 4-Hydroxybenzoic Acid | 5.49 | up |
| 7 | MEDN0554 | C8H10O2 | 2-(4-Hydroxyphenyl)ethanol | 5.47 | up |
| 8 | MW0155866 | C13H19N5O4 | Pro Gly His | 5.28 | up |
| 9 | MEDN0089 | C7H6O4 | 2,5-Dihydroxy Benzoic Acid | 4.98 | up |
| 10 | MEDN1224 | C12H24O17P2 | Bis(1-inositol)-3,1′-phosphate 1-phosphate | −1.66 | down |
| 11 | MEDN0481 | C7H6O4 | 2,4-Dihydroxy Benzoic Acid | 4.98 | up |
| 12 | MEDN1322 | C7H6O4 | 2,3-Dihydroxybenzoic acid | 4.98 | up |
| 13 | MEDN1701 | C7H6O4 | 3,5-Dihydroxybenzoic acid | 4.98 | up |
| 14 | MW0009845 | C16H22ClN3O | Tebuconazole | 4.52 | up |
| 15 | MEDL00416 | C12H24O3 | 3-Hydroxydodecanoic acid | 4.31 | up |
| 16 | MW0013514 | C10H20O3 | 2-Hydroxydecanoate | 4.20 | up |
| 17 | MEDP1280 | C15H22N6O5S | S-Adenosyl-L-Methionine | −1.09 | down |
| 18 | MW0105037 | C10H20O3 | 3-Hydroxycapric acid | 4.14 | up |
| 19 | MEDP1464 | C13H13N3 | 1,3-Diphenylguanidine | −2.27 | down |
| 20 | MEDN1604 | C14H28O3 | 3-hydroxy-tetradecanoic acid | 3.47 | up |
| 21 | MW0015365 | C16H26O3 | 8R-Hydroxy-4Z,6E,10Z-hexadecatrienoic acid | 3.42 | up |
| 22 | MW0111229 | C18H39N | n-Octadecylamine | 3.00 | up |
| 23 | MW0122796 | C18H13ClFN3O | Alpha-hydroxymidazolam | 2.94 | up |
| 24 | MW0141607 | C15H24N2O2 | 17-Hydroxylupanine | 2.86 | up |
| 25 | MW0145377 | C15H26N8O5 | Arg His Ser | 2.81 | up |
| 26 | MW0158148 | C25H28N4O6 | Trp Glu Phe | 2.77 | up |
| 27 | MW0141608 | C22H32O3 | 17-keto-7(Z),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid | 2.70 | up |
| 28 | MW0006902 | C13H13OP | Diphenylmethylphosphine oxide | 2.70 | up |
| 29 | MEDN0380 | C16H30O2 | FFA(16:1) | 2.70 | up |
| 30 | MW0063608 | C30H48O2 | Soyasapogenol C;Sapogenol C | 2.38 | up |
| 31 | MEDN0494 | C20H32O4 | 8,15-Dihete | 2.35 | up |
| 32 | MW0061673 | C18H40NO6P | Phytosphingosine-1-P | 2.24 | up |
| 33 | MW0161385 | C27H44O | (1S)-3-[(Z)-2-[(1R,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-3-en-1-ol | 2.17 | up |
| 34 | MW0011819 | C17H33O7P | 1-(9Z-tetradecenoyl)-glycero-3-phosphate | 2.17 | up |
| 35 | MW0009514 | C23H31NO2 | Proadifen | 2.14 | up |
| 36 | MW0168308 | C21H30O4 | [10]-Dehydrogingerdione | 2.13 | up |
| 37 | MW0150989 | C17H27N5O6 | His Leu Glu | 2.13 | up |
| 38 | MW0009714 | C25H37NO4 | Salmeterol | 2.13 | up |
| 39 | MEDP1032 | C7H6O2 | Salicylaldehyde | 2.13 | up |
| 40 | MW0104504 | C3H8NO5P | 2-Amino-3-phosphonopropionic acid | −1.82 | down |
| 41 | MW0145031 | C22H47NO5 | Aminopentol; AP1 | 2.12 | up |
| 42 | MW0105559 | C6H12N2O4 | Ala-Ser | −1.15 | down |
| 43 | MW0016192 | C25H37NO4 | Bimatoprost | 2.06 | up |
| 44 | MW0007815 | C17H20N2O | Michler’s ketone | 1.80 | up |
| 45 | MW0017120 | C26H34O6 | Cinobufagin | 1.78 | up |
| 46 | MW0012068 | C21H30O3 | 11a-Hydroxyprogesterone | 1.74 | up |
| 47 | MW0132792 | C15H10O5 | 3,7,4′-Trihydroxyflavone | −13.61 | down |
| 48 | MW0158708 | C29H26N2O7 | TyrMe-Nap-OH | 1.70 | up |
| 49 | MW0144201 | C13H15N3O7 | Abu-Asn-OH | 1.65 | up |
| 50 | MW0139399 | C16H12O6 | Pratensein | 1.56 | up |
| 51 | MW0142458 | C17H34O3 | 2-Methoxyhexadecanoic acid | 1.56 | up |
| 52 | MW0123384 | C24H34O7 | Clerodin | 1.53 | up |
| 53 | MW0155978 | C16H27N3O4 | Pro Pro Ile | 1.47 | up |
| 54 | MW0157221 | C30H42O7 | Stigmatellin A; Stigmatellin | 1.43 | up |
| 55 | MW0144075 | C22H39NO5 | 8-iso Prostaglandin F2 | −8.13 | down |
| 56 | MW0137461 | C20H22O3 | Avobenzone | 1.37 | up |
| 57 | MW0015339 | C20H34O5 | 8-iso-13,14-dihydro-15-keto-PGF2a | 1.36 | up |
| 58 | MW0145074 | C25H29NO4 | Ancistrocladine | −11.81 | down |
| 59 | MW0016257 | C22H40O2 | Butyl 9,12-octadecadienoate | 1.30 | up |
| 60 | MW0149681 | C22H40N8O8 | Gln Glu Ile Arg | −1.48 | down |
| 61 | MW0015555 | C17H24O4 | Acetylvalerenolic acid | 1.29 | up |
| 62 | MW0116826 | C21H28O4 | 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol | 1.29 | up |
| 63 | MW0005044 | C13H16O4 | 4-hydroxy-2-methoxy-3-(3-methylbut-2-en-1-yl)benzoic acid | 1.28 | up |
| 64 | MEDP1685 | C18H39NO3 | Phytosphingosine | 1.27 | up |
| 65 | MW0012516 | C22H36O6 | 16,16-Dimethyl-6-ketoprostaglandin E1 | 1.22 | up |
| 66 | MW0143701 | C11H14N4O4S | 5′-S-Methyl-5′-thioinosine; 5′-Deoxy-5′-methylthioinosine; S-Methyl-5′-thioinosine | 1.20 | up |
| 67 | MEDN1516 | C15H10O3 | 6-Hydroxyflavone (6-HF) | 1.16 | up |
| 68 | MW0013392 | C16H33NO2 | 2-aminohexadecanoic acid | 1.12 | up |
| 69 | MW0143692 | C10H10N4O5 | 5′-Oxoinosine; 5′-Dehydroinosine | 1.10 | up |
| 70 | MEDP1360 | C10H15NO6 | Mycosporine glycine | 1.01 | up |
Figure 7Effect of HBA against respiratory enzymes and antioxidant enzymes activity. Note: (A): MDA: malate dehydrogenase; (B): NADH: NADH oxidase; (C): SOD: total superoxide dismutase; (D): GSH-PX: glutathione peroxidase. Columns followed by different letters indicate significantly different scores in the same phase according to Duncan’s multiple range tests at the p < 0.05 significance level.
Figure 8Effect of HBA on membrane permeability of A. avenae subsp. citrulli. Note: Columns followed by different letters indicate significantly different scores in the same phase according to Duncan’s multiple range tests at the p < 0.05 significance level.
Figure 9Cell membrane integrity of HBA against A. avenae subsp. citrulli. Note: (A): CK; (B): 125 μg/mL; (C): 250 μg/mL.
Figure 10Pyruvic acid content effect of HBA against A. avenae subsp. citrulli. Note: Columns followed by different letters indicate significantly different scores in the same phase according to Duncan’s multiple range tests at the p < 0.05 significance level.
Figure 11The theoretical binding mode between HBA and target enzymes and the result were shown by PyMoL 1.7.6. Notes: (A): binding complex of HBA and MDH; (B): binding complex of HBA and NADH oxidase; (C): binding complex of HBA and SOD; (D): binding complex of HBA and GSH-PX.
Figure 12Inhibition molecular mechanism model of HBA against A. avenae subsp. citrulli.